Ovarian cancer is the seventh most common gynaecologic malignancy seen in women.
Majority of the patients with ovarian cancer are diagnosed at the advanced stage making …

Cancer cells resistance to various therapies remains to be a key challenge nowadays. For a
long time, scientists focused on tumor cells themselves for the mechanisms of acquired drug …

Malignant ascites presents a considerable clinical challenge to the management of ovarian
cancer, but also provides a wealth of opportunities for translational research. The …

The reciprocal interplay of cancer cells and host cells is an indispensable prerequisite for
tumor growth and progression. Cells of both the innate and adaptive immune system, in …

The outcome of chemotherapy can be influenced by the host immune system at multiple
levels. Chemotherapy can kill cancer cells by causing them to elicit an immune response or …

Abstract PD-1/PD-L1 blockade has so far shown limited survival benefit for high-grade
ovarian carcinomas. By using paired samples from the NeoPembrOv randomized phase II …

Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis which drives
endothelial cell survival, proliferation, and migration while increasing vascular permeability …

Immunotherapy as a treatment for cancer is a growing field of endeavor but reports of
success have been limited for epithelial ovarian cancer. Overcoming the challenges to …

Ovarian cancer remains a challenging disease for which improved treatments are urgently
needed. Most patients present with advanced disease that is highly responsive to surgery …

Background: Vascular endothelial growth factor action in tumour angiogenesis is well
characterised; nevertheless, it functions as a key element in the promotion of the immune …